Lower Urine Tenofovir Concentrations among Individuals Taking Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
Keyword(s):
Abstract From directly-observed-therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.
Keyword(s):
2019 ◽
2021 ◽
2020 ◽
Vol 168
◽
pp. 112524
◽
Keyword(s):
2019 ◽